Stockreport

BriaCell Reports Outperforming Metastatic Breast Cancer Patients and Standard-Beating Survival Data

BriaCell Therapeutics Corp. - Common Shares  (BCTX) 
PDF 55% of BriaCell patients1 remained alive one year since enrollment in BriaCell’s Phase 2 study, markedly exceeding the survival rate of current standard of care for simi [Read more]